Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.59 (market cap $12.87B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| EMB | XBI | |
|---|---|---|
Market Cap | $12.87B | $10.11B |
Volume | 14,946,002 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $97.74 | $169.55 |
52-Week Low | $90.14 | $104.99 |
Typical Hold Time | 50 Days | 37 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $90.78, down 0.19% with a bearish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at oversold levels. Recent dividend declarations of $0.41-$0.44 per share provide income support, though key valuation ratios remain unavailable for analysis. Technical indicators suggest the stock is testing support levels near $90-$91.
The outlook remains cautious given the bearish technical momentum and limited fundamental data visibility. Income investors may find value in the dividend yield, but the lack of current financial metrics and bearish technical signals suggest near-term pressure. Market sentiment appears mixed with fixed income ETFs seeing inflows while emerging market bonds face AI-driven yield pressures.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
